The Edit Review: $209 Semaglutide, Priced Before the Intake

The Edit sells six compounded prescription protocols out of Austin, Texas, and it does the one thing almost nothing else in this market does: it prints what they cost on the page, in ordinary HTML, to a stranger who has answered no questions. We arrived cold in August 2026 — no account, no email address, no health history — and the entire ladder was already there.

That is not a small compliment, and it is the axis this publication grades telehealth on. Most of what we publish concerns food, fiber and the microbiome, where the cost of a decision is a grocery bill and the evidence is the hard part. Prescription GLP-1 medicine inverts that: the evidence for the molecules is the best-characterized thing in metabolic medicine, and the price is the part that has been made deliberately difficult to see until you have already handed over a medical history you cannot un-hand-over. So openness comes first here and the number comes second, and a dearer program that shows you its figure ranks above a cheaper one that hides it.

The cold-visit test

The test we run is blunt. Open the product page in a clean browser session. Do not create an account, do not enter a ZIP code, do not answer a symptom question. Can you write down what a month costs?

At The Edit you can, on two separate surfaces — a consolidated products page and each individual protocol page — and the two agree with each other down to the dollar.¹ That agreement matters more than it sounds. When a site's summary page and its detail pages disagree, one of them is stale, and a reader has no way to know which. Two surfaces telling the same story is the cheapest possible form of corroboration, and it is the first thing we look for.

The ladder we filed

Semaglutide is $209 a month and tirzepatide is $309 a month on the recurring, cancel-when-you-like rung. There is no membership fee stacked on top, and cancellation takes effect at the end of the period you have already paid for rather than triggering a penalty.

Prepay is offered and it is priced honestly. Three months of semaglutide is $575 billed once, which the page describes as $192 a month; six months is $1,065, described as $178. Tirzepatide runs $855 for three ($285 a month) and $1,575 for six ($263). Every one of those divisions is correct — 575 over 3 is 191.67, 1,065 over 6 is 177.50, 855 over 3 is exactly 285, 1,575 over 6 is 262.50. We checked all four because the most common way a provider lands at the bottom of a price ranking is a prepay total dressed as a monthly rate, and this ladder does not do it.

The $109 on the homepage is a coupon, not a rate

The Edit advertises semaglutide at $109 and tirzepatide at $209. Those are first-order prices — a flat $100 off month one — and if you budget on them you will be surprised in week five. The standing figures are $209 and $309, and they are the ones we file.

This is worth dwelling on because it is the single most common reason a cheap-looking row is wrong. A number reaches the bottom of a ladder precisely when something that is not a recurring medication price has been captured as one: a first-month promotion, a prepay total divided out, a membership fee, or the other molecule's column. The Edit labels its promotion as a promotion, which is why the trap is visible rather than buried.

What else is on the shelf

Beyond the two GLP-1 protocols there is injectable NAD+ at $249 a month, injectable glutathione at $199, injectable sermorelin at $169, and a topical GHK-Cu cream at $129.¹ There is no oral GLP-1, no nasal line, and no research-chemical shelf — the site states in its own words that it does not sell research-use-only compounds. That sentence is worth more than it looks. A meaningful share of this market runs an investigational catalog alongside the prescription one, and a company that declines to is making a choice it did not have to make.

Who writes the prescription, and who compounds it

Clinical work sits with Arora Health & Aesthetics, LLC, whose medical director is Dr. Sean Arora. We looked his NPI — 1841729449 — up in the national registry and it resolves to an active Family Medicine record in Seattle, Washington.² Dispensing is attributed to The Pharmacy Hub, named outright rather than described as "our pharmacy partner".

Naming a prescriber you can verify and naming the pharmacy that actually makes the drug are the two disclosures most of this cohort skips. A compounded medicine is a preparation, not a product off a production line, and the pharmacy that prepares it is the single most consequential fact about it. The Edit publishes both.

If Trellis Vitality is also on your list, read this part

Trellis Vitality runs on the same medical group — Arora Health & Aesthetics — and the same medical director, Dr. Sean Arora. It uses a different pharmacy and a different price ladder, so these are genuinely separable products. But if you shortlist both and think of the second as a second clinical opinion, you are shortlisting one clinical organization twice. We say the same thing in the Trellis review, in the same place, for the same reason.

The Spanish site is real, and no other row here does this

The Edit ships a complete Spanish mirror — not a translated landing page, but every page, with 33 Spanish URLs declared in its own sitemap. If Spanish is the language you would rather read your dosing instructions in, that is a material difference rather than a marketing one, and it is the only example of it among the seven operators we screened in this batch.

The warning-letter screen, and why the control matters

We queried the FDA's live warning-letter index for the company, for its legal entity, for its medical group and for its named pharmacy. Nothing matched in the company column.³

That result only carries information because the same pass, run identically, was checked against a company we knew had a real 2026 letter — and it returned it. An empty result from a broken query is indistinguishable on screen from a clean record, so a screen without a positive control tells you nothing at all. Ours had one.

What we could not see

We could not reach a checkout price. The intake sits behind a questionnaire and its scripts carry no price table, so what we are reporting is the published ladder, corroborated across two surfaces on the company's own site, not a figure confirmed at the point of sale. We would rather say that plainly than imply a confirmation we do not have.

Getting started costs nothing: the site states there is no charge and no card on file to begin, with a full refund if you are not approved. Compounded medication is final sale once shipped, which is standard across the category rather than a quirk of this seller.

The gut part, because this is that kind of publication

Whatever you pay, the side effect that most often ends a GLP-1 course is gastrointestinal — nausea, constipation, reflux — and in the pivotal semaglutide trials GI events were both the commonest adverse events and a meaningful driver of discontinuation.⁴ That is a tolerability problem, not a pricing one, but it interacts with pricing in a way worth naming: a six-month prepay is a bet that you will still be taking the drug in month six. If you are weighing that bet, our notes on gut symptoms while you are on a GLP-1 and on bloating during titration are more useful to you than any price table.

Where it lands

On the axis this site actually scores — can a stranger read the price — The Edit is the strongest of the seven operators we screened together. It is not the cheapest: Pepti prints $99 semaglutide and Trellis Vitality prints $150, and Auren Rx undercuts it at $199. It is the one whose published numbers survived every arithmetic check we could run against them.

We take no commission from The Edit and have no relationship with it; there is nothing to click here and nothing for us in your clicking it. The programs this site does link out to are graded on the same axis and put in order on it in our compounded semaglutide ranking, where a program appears at all only if it publishes a semaglutide price before the intake. If a prescription is not where you want to start, the rest of this library — beginning with the research index — is mostly about the version of this problem you can solve with food.